Drug
Topical imiquimod
Topical imiquimod is a pharmaceutical drug with 3 clinical trials. Currently 1 active trials ongoing.
Total Trials
3
Max Phase
—
Type
DRUG
Molecule
—
Success Metrics
Completion Rate
0%(0/2)
Active Trials
1(33%)
Terminated
2(67%)
Phase Distribution
Ph phase_3
1
33%
Ph phase_1
2
67%
Phase Distribution
2
Early Stage
0
Mid Stage
1
Late Stage
Phase Distribution3 total trials
Phase 1Safety & dosage
2(66.7%)
Phase 3Large-scale testing
1(33.3%)
Highest Phase Reached
Phase 3Trial Status & Enrollment
Completion Rate
0.0%
0 of 2 finished
Non-Completion Rate
100.0%
2 ended early
Currently Active
1
trials recruiting
Total Trials
3
all time
Status Distribution
Active(1)
Terminated(2)
Detailed Status
Terminated2
Recruiting1
Development Timeline
Analytics
Development Status
Total Trials
3
Active
1
Success Rate
0.0%
Most Advanced
Phase 3
Trials by Phase
Phase 12 (66.7%)
Phase 31 (33.3%)
Trials by Status
terminated267%
recruiting133%
Recent Activity
1 active trials
Showing 3 of 3
recruitingphase_1
Cemiplimab Plus Imiquimod and Laser Therapy As Neoadjuvant Treatment In Cutaneous Basal Cell Carcinoma
NCT07251413
terminatedphase_1
Epicutaneous Cryoimmunotherapy Combined With Pembrolizumab for Cutaneous Metastatic Breast Cancer
NCT03982004
terminatedphase_3
Topical Imiquimod Versus Conization to Treat Cervical Intraepithelial Neoplasia
NCT01283763
Clinical Trials (3)
Showing 3 of 3 trials
NCT07251413Phase 1
Cemiplimab Plus Imiquimod and Laser Therapy As Neoadjuvant Treatment In Cutaneous Basal Cell Carcinoma
NCT03982004Phase 1
Epicutaneous Cryoimmunotherapy Combined With Pembrolizumab for Cutaneous Metastatic Breast Cancer
NCT01283763Phase 3
Topical Imiquimod Versus Conization to Treat Cervical Intraepithelial Neoplasia
All 3 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 3